CuraVac was created by MG patients for MG patients with the goal of developing a safe and efficacious treatment for Myasthenia Gravis : the MG Therapeutic Vaccine (CV-MG01).
The treatment, based on the work of Professor Blalock and his team at the University of Alabama at Birmingham (UAB) aims to specifically neutralize only the antibodies and cells in the immune system involved in MG.
The first-in-human trial was carried out in the framework of the Myasterix project supported by the European Commission. The phase 1 clinical trial was completed in September 2018 and demonstrated positive results and an excellent safety profile.
The development team is now actively preparing an efficacy clinical trial with a more potent version of the MG Therapeutic Vaccine (CV-MG02).
This survey aims to determine if there is currently a real interest in the only curative treatment for Myasthenia Gravis in development.
The number of replies and the quality of them will serve as leverage for CuraVac to help to lift the last financial barriers it faces in order to prepare and conduct Phase 2: an efficacy clinical trial on a group of 32 patients.
At CuraVac we know that Myasthenia Gravis affects not only the patients but also their loved ones (spouses, families, friends, …)
Please share this survey with as many people as possible so that their answers can help us to convince our different partners (scientists, doctors, politicians, financial partners, …) of the interest the patient community and their loved ones have in this novel treatment.